Investigational New Drugs

, Volume 33, Issue 1, pp 32–44 | Cite as

Identification of cellular and molecular factors determining the response of cancer cells to six ergot alkaloids

  • Marco Mrusek
  • Ean-Jeong Seo
  • Henry Johannes Greten
  • Michael Simon
  • Thomas Efferth
PRECLINICAL STUDIES
First Online:
Received:
Accepted:

Summary

Ergot alkaloids are psychoactive and vasoconstricting agents of the fungus Claviceps purpurea causing poisoning such as ergotism in medieval times (St. Anthony’s Fire). This class of substances also inhibits tumor growth in vitro and in vivo, though the underlying mechanisms are unclear as yet. We investigated six ergot alkaloids (agroclavine, ergosterol, ergocornin E, ergotamine, dihydroergocristine, and 1-propylagroclavine tartrate) for their cytotoxicity towards tumor cell lines of the National Cancer Institute, USA. 1-Propylagroclavine tartrate (1-PAT) revealed the strongest cytotoxicity. Out of 76 clinically established anticancer drugs, cross-resistance was found between the ergot alkaloids and 6/7 anti-hormonal drugs (=85.7 %) and 5/15 DNA-alkylating drugs (=33.3 %). The IC50 values for the six alkaloids were not correlated to well-known determinants of drug resistance, such as proliferative activity (as measured by cell doubling times, PCNA expression, and cell cycle distribution), the multidrug resistance-mediating P-glycoprotein/MDR1 and expression or mutations of oncogenes and tumor suppressor genes (EGFR, RAS, TP53). While resistance of control drugs (daunorubicin, cisplatin, erlotinib) correlated with these classical resistance mechanisms, ergot alkaloids did not. Furthermore, COMPARE and hierarchical cluster analyses were performed of mRNA microarray data to identify genes correlating with sensitivity or resistance to 1-PAT. Twenty-three genes were found with different biological functions (signal transducers, RNA metabolism, ribosome constituents, cell cycle and apoptosis regulators etc.). The expression of only 3/66 neuroreceptor genes correlated with the IC50 values for 1-PAT, suggesting that the psychoactive effects of ergot alkaloids may not play a major role for the cytotoxic activity against cancer cells. In conclusion, the cytotoxicity of ergot alkaloids is not involved in classical mechanisms of drug resistance opening the possibility to bypass resistance and to treat otherwise drug-resistant and refractory tumors. The modes of action are multifactorial, which is a typical feature of many natural compounds.

Keywords

Alkaloids Cancer Claviceps purpurea Clavicipitaceae Microarrays Pharmacogenomics 
This is a preview of subscription content, log in to check access.

Notes

Conflict of interest

The authors declare that they have no conflict of interest.

References

  1. 1.
    Hesseltine CW (1974) Natural Occurence of Mycotoxins in Cereals. Mycopathol Mycol Applic 53:141–153CrossRefGoogle Scholar
  2. 2.
    Mulac D, Lepski S, Ebert F, Schwerdtle T, Humpf HU (2013) Cytotoxicity and Fluorescence Visualization of Ergot Alkaloids in Human Cell Lines. J Agricult Food Chem 61:462–471CrossRefGoogle Scholar
  3. 3.
    Ayarragaray JE (2013) Ergotism: A Change of Persepective. Ann Vasc Surg 2013 [epub ahead of print]Google Scholar
  4. 4.
    Houghton PJ, Howes MJ (2005) Natural products and derivatives affecting neurotransmission relevant to Alzheimer’s and Parkinson’s disease. Neurosignals 14:6–22PubMedCrossRefGoogle Scholar
  5. 5.
    Tepper SJ (2013) Orally inhaled dihydroergotamine: a review. Headache 53(Suppl 2):43–53PubMedCrossRefGoogle Scholar
  6. 6.
    Gizzo S, Patrelli TS, Gangi SD, Carrozzini M, Saccardi C, Zambon A, Bertocco A, Fagherazzi S, D'Antona D, Nardelli GB (2013) Which uterotonic is better to prevent the postpartum hemorrhage? Latest news in terms of clinical efficacy, side effects, and contraindications: a systematic review. Reprod Sci 20:1011–1019PubMedCrossRefGoogle Scholar
  7. 7.
    Li SM, Unsöld IA (2006) Post-genome research on the biosynthesis of ergot alkaloids. Planta Med 72:1117–1120PubMedCrossRefGoogle Scholar
  8. 8.
    Alley MC, Scudiero DA, Monks A, Hursey ML, Czerwinski MJ, Fine DL, Abbott BJ, Mayo JG, Shoemaker RH, Boyd MR (1988) Feasibility of drug screening with panels of human tumor cell lines using a microculture tetrazolium assay. Cancer Res 48:589–601PubMedGoogle Scholar
  9. 9.
    Rubinstein LV, Shoemaker RH, Paull KD, Simon RM, Tosini S, Skehan P, Scudiero DA, Monks A, Boyd MR (1990) Comparison of in vitro anticancer-drug screening data generated with a tetrazolium assay versus a protein assay against a diverse panel of human tumor cell lines. J Natl Cancer Inst 82:1113–1118PubMedCrossRefGoogle Scholar
  10. 10.
    Scherf U, Ross DT, Waltham M, Smith LH, Lee JK, Tanabe L, Kohn KW, Reinhold WC, Myers TG, Andrews DT, Scudiero DA, Eisen MB, Sausville EA, Pommier Y, Botstein D, Brown PO, Weinstein JN (2000) A gene expression database for the molecular pharmacology of cancer. Nat Genet 24:236–244PubMedCrossRefGoogle Scholar
  11. 11.
    Amundson SA, Do KT, Vinikoor LC, Lee RA, Koch-Paiz CA, Ahn J, Reimers M, Chen Y, Scudiero DA, Weinstein JN, Trent JM, Bittner ML, Meltzer PS, Fornace AJ Jr (2008) Integrating global gene expression and radiation survival parameters across the 60 cell lines of the National Cancer Institute Anticancer Drug Screen. Cancer Res 68:415–424PubMedCrossRefGoogle Scholar
  12. 12.
    Efferth T, Fabry U, Osieka R (1997) Apoptosis and resistance to daunorubicin in human leukemic cells. Leukemia 11:1180–1186PubMedCrossRefGoogle Scholar
  13. 13.
    Efferth T, Herrmann F, Tahrani A, Wink M (2011) Cytotoxic activity of secondary metabolites derived from Artemisia annua L. towards cancer cells in comparison to its designated active constituent artemisinin. Phytomedicine 18:959–969PubMedCrossRefGoogle Scholar
  14. 14.
    Volm M, Koomägi R, Mattern J, Efferth T (2002) Protein expression profiles indicative for drug resistance of non-small cell lung cancer. Br J Cancer 87:251–257PubMedCentralPubMedCrossRefGoogle Scholar
  15. 15.
    Wosikowski K, Silverman JA, Bishop P, Mendelsohn J, Bates SE (2000) Reduced growth rate accompanied by aberrant epidermal growth factor signaling in drug resistant human breast cancer cells. Biochim Biophys Acta 1497:215–226PubMedCrossRefGoogle Scholar
  16. 16.
    Efferth T, Koch E (2011) Complex interactions between phytochemicals. The multi-target therapeutic concept of phytotherapy. Curr Drug Targets 12:122–132PubMedCrossRefGoogle Scholar
  17. 17.
    Efferth T, Konkimalla VB, Wang YF, Sauerbrey A, Meinhardt S, Zintl F, Mattern J, Volm M (2008) Prediction of broad spectrum resistance of tumors towards anticancer drugs. Clin Cancer Res 14(8):2405–2412PubMedCrossRefGoogle Scholar
  18. 18.
    El-Deiry WS (2003) The role of p53 in chemosensitivity and radiosensitivity. Oncogene 22:7486–7495PubMedCrossRefGoogle Scholar
  19. 19.
    Sklar MD (1988) The ras oncogenes increase the intrinsic resistance of NIH 3 T3 cells to ionizing radiation. Science 239:645–647PubMedCrossRefGoogle Scholar
  20. 20.
    Sklar MD (1988b) Increased resistance to cis-diamminedichloroplatinum (II) in NIH 3 T3 cells transformed by ras oncogenes. Cancer Res48:793–797 Erratum in: Cancer Res 1988;48 (13):3889.
  21. 21.
    Eich E, Eichberg D, Clavines MWE (1984) New antibiotics with cytostatic activity. Biochem Pharmacol 33:523–526PubMedCrossRefGoogle Scholar
  22. 22.
    Eich E, Becker C, Mayer K, Maidhof A, Müller WE (1986) Clavines as antitumor agents; 2. Natural 8-hydroxymethyl-ergoline type clavines and their derivatives. Planta Med 4:290–294PubMedCrossRefGoogle Scholar
  23. 23.
    Faatz W, Pertz H, Maidhof A, Müller WEG, Eich E (1989) Antitumor compounds derived from the ergot minor alkaloid pyroclavine. Planta Med 55:653–654CrossRefGoogle Scholar
  24. 24.
    Eich E, Pertz H (1999) antimicrobial and antitumor effects of ergot alkaloidfs and their derivatives. In: Kren V, Cvak L (eds.) Ergot. The genus claviceps. Harwood Academic PublishersGoogle Scholar
  25. 25.
    Efferth T, Olbrich A, Bauer R (2002) mRNA expression profiles for the response of human tumor cell lines to the antimalarial drugs artesunate, arteether, and artemether. Biochem Pharmacol 64:617–623PubMedCrossRefGoogle Scholar
  26. 26.
    Sertel S, Eichhorn T, Bauer J, Hock K, Plinkert PK, Efferth T (2012) Pharmacogenomic determination of genes associated with sensitivity or resistance of tumor cells to curcumin and curcumin derivatives. J Nutr Biochem 23:875–884PubMedCrossRefGoogle Scholar
  27. 27.
    Efferth T, Miyachi H, Bartsch H (2007) Pharmacogenomics of a traditional Japanese herbal medicine (Kampo) for cancer therapy. Cancer Genomics Proteomics 4:81–92PubMedGoogle Scholar
  28. 28.
    Wiench B, Chen YR, Paulsen M, Hamm R, Schröder S, Yang NS, Efferth T (2013) Integration of different ”-omics” technologies identifies inhibition of the IGF1R-Akt-mTOR signaling cascade involved in the cytotoxic effect of shikonin against leukemia cells. Evid Based Complement Alternat Med 2013:818709PubMedCentralPubMedCrossRefGoogle Scholar
  29. 29.
    Thornier MO, Flückinger E, Calne DB (1980) Bromocriptine, a clinical and pharmacological review. Raven Press New, YorkGoogle Scholar
  30. 30.
    Glatt H, Eich E, Pertz H, Becker C, Oesch F (1987) Mutagenicity experiments on agroclavines, new natural antineoplastic compounds. Cancer Res 47:1811–1814PubMedGoogle Scholar
  31. 31.
    Glatt H, Pertz H, Kasper R, Eich E (1992) Clavine alkaloids and derivatives as mutagens detected in the Ames test. Anticancer Drugs 3:609–614PubMedCrossRefGoogle Scholar
  32. 32.
    Efferth T (2001) The human ATP-binding cassette transporter genes: from the bench to the bedside. Curr Mol Med 1:45–65PubMedCrossRefGoogle Scholar
  33. 33.
    Gillet JP, Efferth T, Remacle J (2007) Chemotherapy-induced resistance by ATP-binding cassette transporter genes. Biochim Biophys Acta 1775:237–262PubMedGoogle Scholar
  34. 34.
    Gottesman MM, Ling V (2006) The molecular basis of multidrug resistance in cancer: the early years of P-glycoprotein research. FEBS Lett 580:998–1009PubMedCrossRefGoogle Scholar
  35. 35.
    Yasuda K, Lan LB, Sanglard D, Furuya K, Schuetz JD, Schuetz EG (2002) Interaction of cytochrome P450 3A inhibitors with P-glycoprotein. J Pharmacol Exp Ther 303:323–332PubMedCrossRefGoogle Scholar
  36. 36.
    Orlowski S, Valente D, Garrigos M, Ezan E (1998) Bromocriptine modulates P-glycoprotein function. Biochem Biophys Res Commun 244:481–488PubMedCrossRefGoogle Scholar
  37. 37.
    Goh AM, Coffill CR, Lane DP (2011) The role of mutant p53 in human cancer. J Pathol 223:116–126PubMedCrossRefGoogle Scholar
  38. 38.
    Müller M, Schleithoff ES, Stremmel W, Melino G, Krammer PH, Schilling T (2006) One, two, three–p53, p63, p73 and chemosensitivity. Drug Resist Updat 9:288–306PubMedCrossRefGoogle Scholar
  39. 39.
    Mulac D, Humpf HU (2011) Cytotoxicity and accumulation of ergot alkaloids in human primary cells. Toxicology 282:112–121PubMedCrossRefGoogle Scholar
  40. 40.
    Mulac D, Lepski S, Ebert F, Schwerdtle T, Humpf HU (2013) Cytotoxicity and fluorescence visualization of ergot alkaloids in human cell lines. J Agric Food Chem 61:462–471PubMedCrossRefGoogle Scholar
  41. 41.
    El-Deiry WS (1997) Role of oncogenes in resistance and killing by cancer therapeutic agents. Curr Opin Oncol 9:79–87PubMedCrossRefGoogle Scholar
  42. 42.
    Evans A, Bates V, Troy H, Hewitt S, Holbeck S, Chung YL, Phillips R, Stubbs M, Griffiths J, Airley R (2008) Glut-1 as a therapeutic target: increased chemoresistance and HIF-1-independent link with cell turnover is revealed through COMPARE analysis and metabolomic studies. Cancer Chemother Pharmacol 61:377–393PubMedCrossRefGoogle Scholar
  43. 43.
    Fagan V, Bonham S, Carty MP, Saenz-Méndez P, Eriksson LA, Aldabbagh F (2012) COMPARE analysis of the toxicity of an iminoquinone derivative of the imidazo [5,4-f] benzimidazoles with NAD (P) H:quinone oxidoreductase 1 (NQO1) activity and computational docking of quinones as NQO1 substrates. Bioorg Med Chem 20:3223–3232PubMedCrossRefGoogle Scholar
  44. 44.
    Luzina EL, Popov AV (2012) Synthesis, evaluation of anticancer activity and COMPARE analysis of N-bis (trifluoromethyl) alkyl-N’-substituted ureas with pharmacophoric moieties. Eur J Med Chem 53:364–373PubMedCrossRefGoogle Scholar
  45. 45.
    Villeneuve DJ, Parissenti AM (2004) The use of DNA microarrays to investigate the pharmacogenomics of drug response in living systems. Curr Top Med Chem 4:1329–1345PubMedCrossRefGoogle Scholar
  46. 46.
    Zeeberg BR, Liu H, Kahn AB, Ehler M, Rajapakse VN, Bonner RF, Brown JD, Brooks BP, Larionov VL, Reinhold W, Weinstein JN, Pommier YG (2011) RedundancyMiner: De-replication of redundant GO categories in microarray and proteomics analysis. BMC Bioinformatics 12:52PubMedCentralPubMedCrossRefGoogle Scholar
  47. 47.
    Jahangiri A, De Lay M, Miller LM, Carbonell WS, Hu YL, Lu K, Tom MW, Paquette J, Tokuyasu TA, Tsao S, Marshall R, Perry A, Bjorgan KM, Chaumeil MM, Ronen SM, Bergers G, Aghi MK (2013) Gene expression profile identifies tyrosine kinase c-Met as a targetable mediator of antiangiogenic therapy resistance. Clin Cancer Res 19:1773–1783PubMedCentralPubMedCrossRefGoogle Scholar
  48. 48.
    Reinhold WC, Sunshine M, Liu H, Varma S, Kohn KW, Morris J, Doroshow J, Pommier Y (2012) Cell Miner: a web-based suite of genomic and pharmacologic tools to explore transcript and drug patterns in the NCI-60 cell line set. Cancer Res 72:3499–3511PubMedCentralPubMedCrossRefGoogle Scholar
  49. 49.
    Efferth T (2012) Signal transduction pathways of the epidermal growth factor receptor in colorectal cancer and their inhibition by small molecules. Curr Med Chem 19:5735–5744PubMedCrossRefGoogle Scholar
  50. 50.
    Varlakhanova NV, Knoepfler PS (2009) Acting locally and globally: Myc‘s ever-expanding roles on chromatin. Cancer Res 69:7487–7490PubMedCrossRefGoogle Scholar
  51. 51.
    Torigoe T, Izumi H, Ishiguchi H, Yoshida Y, Tanabe M, Yoshida T, Igarashi T, Niina I, Wakasugi T, Imaizumi T, Momii Y, Kuwano M, Kohno K (2005) Cisplatin resistance and transcription factors. Curr Med Chem Anticancer Agents 5:15–27PubMedCrossRefGoogle Scholar
  52. 52.
    Lambert T (2012) Antibiotics that affect the ribosome. Rev Sci Tech 31:57–64PubMedGoogle Scholar
  53. 53.
    McCusker KP, Fujimori DG (2012) The chemistry of peptidyltransferase center-targeted antibiotics: enzymatic resistance and approaches to countering resistance. ACS Chem Biol 7:64–72PubMedCentralPubMedCrossRefGoogle Scholar
  54. 54.
    Keenan J, Murphy L, Henry M, Meleady P, Clynes M (2009) Proteomic analysis of multidrug-resistance mechanisms in adriamycin-resistant variants of DLKP, a squamous lung cancer cell line. Proteomics 9:1556–1566PubMedCrossRefGoogle Scholar
  55. 55.
    Larson BT, Samford MD, Camden JM, Piper EL, Kerley MS, Paterson JA, Turner JT (1995) Ergovaline binding and activation of D2 dopamine receptors in GH4ZR7 cells. J Anim Sci 73:1396–1400PubMedGoogle Scholar
  56. 56.
    Pertz H (1996) Naturally occurring clavines: antagonism/partial agonism at 5-HT2A receptors and antagonism at alpha 1-adrenoceptors in blood vessels. Planta Med 62:387–392PubMedCrossRefGoogle Scholar
  57. 57.
    Eich E, Becker C, Sieben R, Maidhof A, Müller WE (1986) Clavines as antitumor agents, 3: Cytostatic activity and structure/activity relationships of 1-alkyl agroclavines and 6-alkyl 6-noragroclavines. J Antibiot 39:804–812PubMedCrossRefGoogle Scholar
  58. 58.
    Eich E, Pertz H, Müller WEG (1987) Neuen Festuclavin- und Pyroclavin-derivate, Verfahren zu ihrer Herstellung und deren Verwendung als Arzneimittel. Offenlegungsschrift deutsches Patentamt DE 37 30 124 (16.09.1989)Google Scholar

Copyright information

© Springer Science+Business Media New York 2014

Authors and Affiliations

  • Marco Mrusek
    • 1
  • Ean-Jeong Seo
    • 2
  • Henry Johannes Greten
    • 3
    • 4
  • Michael Simon
    • 1
  • Thomas Efferth
    • 2
  1. 1.Institute of Cultural AnthropologyJohannes Gutenberg UniversityMainzGermany
  2. 2.Department of Pharmaceutical Biology Institute of Pharmacy and BiochemistryJohannes Gutenberg UniversityMainzGermany
  3. 3.Biomedical Sciences Institute Abel SalazarUniversity of PortoLisbonPortugal
  4. 4.Heidelberg School of Chinese MedicineHeidelbergGermany

Personalised recommendations